[144] Quest Diagnostics Inc. SEC Filing

Rhea-AI Filing Summary

Quest Diagnostics Inc. (DGX) has filed a Form 144 indicating an intended sale of 8,269 common shares through Fidelity Brokerage Services.

• Aggregate market value: $1,384,230.60 (based on the market price on the filing date).
• Percentage of shares outstanding: approx. 0.0074 % of the 111,823,441 shares outstanding — an immaterial level.
• Anticipated sale date: 07 / 30 / 2025 on the NYSE.
• Source of shares: options granted on 18 Feb 2019 (3,045 shares) and 18 Feb 2020 (5,224 shares); cash was paid upon exercise.

No shares were sold during the prior three months, and the signer represents no undisclosed adverse information. The filer’s name, relationship to the issuer, and 10b5-1 plan data were not disclosed in the excerpt.

Positive

• Immaterial size: planned sale represents only about 0.007 % of outstanding shares, limiting dilution or market impact.

Negative

• Insider selling signal: any insider liquidation, however small, can be viewed bearish if investors fear management’s outlook.

Insights

Equity Analyst

TL;DR – Minor insider sale: 0.007 % of float; likely negligible market impact.

The Form 144 signals a planned disposal of just 8,269 DGX shares worth roughly $1.4 million. Relative to Quest Diagnostics’ >111 million share base and $15 billion market cap, the sale is de-minimis and should not alter supply–demand dynamics. Such option-related sales are routine for executives to cover taxes or diversify. Absence of prior-quarter sales and the required attestation of no undisclosed negative information reduce concern. Still, insider selling may be perceived cautiously amid any broader weakness in the diagnostics sector.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	8269	1384230.60	111823441	07/30/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/30/2025	Option Granted - 02/18/2019	Issuer			3045	07/30/2025	Cash
Common	07/30/2025	Option Granted - 02/18/2020	Issuer			5224	07/30/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Quest Diagnostics (DGX) shares are being sold under this Form 144?

8,269 common shares are slated for sale.

What is the total market value of the DGX shares to be sold?

The aggregate market value is $1,384,230.60.

When is the anticipated sale date for the DGX shares?

The filer plans to sell on 07/30/2025.

What percentage of Quest Diagnostics’ outstanding shares does this sale represent?

Approximately 0.0074 % of the 111,823,441 shares outstanding.

How were the shares acquired by the seller?

They came from stock options granted on 18 Feb 2019 (3,045 shares) and 18 Feb 2020 (5,224 shares), exercised for cash.